Date: {{$ActivityAssignDate}}

Dear Dr. {{ $doctorName }},

Subject : Evaluation of treatment approaches for suspected underactive bladder (UAB): Clinical preference and patient outcomes

Prostate cancer (PC), is the world’s second most common cancer among men. It accounts for approximately 14.2% of new cancer cases in men, with an age-adjusted incidence rate of 29.4 per 100,000 population. (Sankarapillai J et al 2024) The Indian Council of Medical Research reported an incidence rate of 9–10/100,000 population, higher compared to other countries in Asia/Africa, but lower when compared to the United States (US)/Europe. (Bakshi G et al 2022) Poverty, poor socio-economic status, illiteracy and a lack of knowledge of the disease symptoms are some of the factors responsible for late presentation. (Benedict MA et al 2023)

The recent increase in the PC incidence in India can be primarily attributed to the increased migration of the rural population to urban areas, changing dietary and lifestyle habits, and increased awareness and easier access to medical facilities in urban areas. However, India being a vast country has marked differences in detection practices, access, affordability, and availability of treatment modalities across different regions. The overall low disease awareness, disparate medical care access, late diagnosis, inadequate documentation, and lack of robust PC data in Indian patients make the management of PC difficult. (Benedict MA et al 2023)

The landscape of PC management has undergone major shifts in recent years because of evolving modalities of imaging and novel therapies. (Benedict MA et al 2023) The objective of this survey is to evaluate current practice of Urologists, their perception in management of Prostate Cancer.

As you will be spending some extra time to give your feedback on the questionnaire based on your clinical experience, we offer to pay you by cheque a professional fee of INR {{$contractAmount}} on receiving the completed Survey Questionnaire Form from you.

We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.